IVX Health Secures $100 Million Growth Investment from Great Hill Partners to Accelerate New Market Expansion
IVX Health has announced the completion of a $100 million Series F minority investment from private equity firm Great Hill Partners. Previous investors in IVX Health include Linden Structured Capital, McKesson Ventures, Health Velocity Capital, and Nueterra Capital.
IVX Health operates over 50 infusion centers across 16 markets, where it offers infusion services to patients in a comfortable, convenient, and cost-effective way. The company will use the additional funding to expand its operations to new markets, where it will serve patients with complex chronic conditions such as MS, Crohn’s disease, rheumatoid arthritis, and more.
“Our primary goal has always been to provide world-class service and clinical excellence to the patients we serve,” said IVX Health CEO, Doug Ghertner. “IVX and Great Hill both see an inflection point in infusion therapy, as the growth in diagnosed autoimmune conditions and trends toward patient choice have aligned with an uptick in innovative new therapies. Many patients are unfortunately still left with few options for receiving this life-changing care, often within a crowded infusion room of a hospital – and that’s where we come in. We are confident that Great Hill’s investment and deep domain expertise will help us address this shortage of care options by enabling IVX to bring our unique clinical model and patient-centered amenities to an even broader universe of patients.”
In addition to the investment, Great Hill Managing Director Mark Taber will join the IVX Health Board of Directors.
Read the full press release on BusinessWire.